Kenneth Krogulski - 05 Sep 2023 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)

Role
Director
Signature
Kenneth J. Krogulski by /s/ John Hamm as attorney-in-fact
Issuer symbol
CPIX
Transactions as of
05 Sep 2023
Net transactions value
+$4,704
Form type
4
Filing time
19 Sep 2023, 09:24:10 UTC
Previous filing
08 Sep 2023
Next filing
03 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $556 +325 +0.15% $1.71 214,019 05 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $546 +325 +0.15% $1.68 214,344 06 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $556 +325 +0.15% $1.71 214,669 07 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $556 +325 +0.15% $1.71 214,994 08 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $566 +325 +0.15% $1.74 215,319 11 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $582 +325 +0.15% $1.79 215,644 12 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $604 +325 +0.15% $1.86 215,969 13 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $608 +325 +0.15% $1.87 216,294 14 Sep 2023 Direct F1
transaction CPIX Common Stock Small acquisition under Rule 16a-6 $131 +72 +0.03% $1.82 216,366 15 Sep 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.